A population-based study evaluating the
β
Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bu
π
Article
π
2009
π
John Wiley and Sons
π
English
β 183 KB
π 1 views
## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a firstβline standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH